William Dewar
Internal Medicine · Honesdale, PANPI 1346202744
Payments from drug & device makers
Across 146 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$312
- GSK$273
- AbbVie$261
- Johnson & Johnson$246
- Novo Nordisk$234
- Pfizer$137
- plus $847 from 23 others
What the payments were for
- Food & beverage$2,305100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 18 | $312 |
| GSK | 18 | $273 |
| AbbVie(2 entities) | 16 | $261 |
| Johnson & Johnson | 17 | $246 |
| Novo Nordisk | 16 | $234 |
| Pfizer | 7 | $137 |
| Bayer | 7 | $127 |
| Amgen | 8 | $122 |
| Astellas Pharma US Inc | 5 | $73 |
| AstraZeneca(2 entities) | 5 | $69 |
| Biogen | 3 | $52 |
| Eisai Inc. | 2 | $46 |
| Novartis | 3 | $38 |
| Nestle Healthcare Nutrition Inc. | 3 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Dexcom, Inc. | 2 | $27 |
| Abbott | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Merck | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
How this compares
$2,310 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 333 | $95,626 |
| MyrbetriqMirabegron | 145 | $32,031 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 85 | $25,843 |
| XareltoRivaroxaban | 84 | $22,957 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $19,595 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 161 | $19,576 |
| EntrestoSacubitril/Valsartan | 20 | $14,464 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 67 | $13,710 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $9,838 |
| JanuviaSitagliptin Phosphate | 31 | $8,895 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $8,179 |
| Potassium Chloride | 314 | $6,634 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,578 |
| Atorvastatin Calcium | 544 | $5,433 |
| Memantine Hcl | 139 | $5,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $137 | $121,468418 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $273 | $39,883110 claims |
| Astellas Pharma US IncMyrbetriq | $73 | $32,031145 claims |
| Johnson & JohnsonXarelto, Invokana | $246 | $25,03797 claims |
| NovartisEntresto | $38 | $14,46420 claims |
| MerckJanuvia | $16 | $8,89531 claims |
| Boehringer IngelheimJardiance | $34 | $4,85218 claims |
| AstraZenecaFarxiga | $69 | $4,06315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Honesdale
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.